Regeneron Pharmaceuticals (REGN) Non Operating Income (2009 - 2026)

Regeneron Pharmaceuticals' Non Operating Income history runs 18 years deep, the most recent figure standing at $188.3 million for Q1 2026.

• On a quarterly basis, Non Operating Income fell 39.9% year-over-year to $188.3 million in Q1 2026; TTM through Mar 2026 was $1.5 billion, a 32.48% increase from a year earlier, with the FY2025 full-year figure at $1.7 billion, up 109.43% from the prior year.
• Non Operating Income grew to $188.3 million in Q1 2026 per REGN's latest filing, from $163.8 million in the prior quarter.
• Across five years, Non Operating Income topped out at $736.5 million in Q3 2025 and bottomed at -$197.4 million in Q1 2022.
• The 5-year median for Non Operating Income is $174.7 million (2023), against an average of $170.7 million.
• Across the five-year window, Non Operating Income slumped 240.7% in 2022 and surged 156850.0% in 2024, its largest moves.
• Year by year, Non Operating Income stood at $177.9 million in 2022, then declined by 1.8% to $174.7 million in 2023, then slumped by 118.37% to -$32.1 million in 2024, then surged by 610.28% to $163.8 million in 2025, then rose by 14.96% to $188.3 million in 2026.
• Per Business Quant, the three latest REGN Non Operating Income figures stand at $188.3 million (Q1 2026), $163.8 million (Q4 2025), and $736.5 million (Q3 2025).